OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

In newly diagnosed GBM,

Results of a post hoc analysis of the EF-14 study showed Optune + TMZ was associated with increased median OS vs TMZ alone in patients ineligible for surgical resection1

The EF-14 pivotal phase 3 trial included patients with newly diagnosed GBM who only had a biopsy1

  • Patients who did not have a resection had a biopsy1

Extent of Resection was consistent across both study arms1

The extent of resection was consistent across both study arms

The study protocol defined surgery as surgical resection to the extent safely feasible or biopsy.1

OS data from a post-hoc analysis of biopsy-only patients in the EF-14 study (Optune® + TMZ vs TMZ alone)
  • In the EF-14 trial1
    • 13% of patients in each study arm only had a biopsy
    • 3 patients treated with Optune + TMZ and 1 patient in the TMZ alone group were included in the analysis at 48 months2

In a post hoc analysis, extension of OS was observed with Optune + TMZ across all patient subgroups vs TMZ alone1*

  • In patients who had a partial resection, median OS was 21.4 months with Optune + TMZ (n=157) compared with 15.1 months with TMZ alone (n=77)1
  • In patients who had a gross total resection, median OS was 22.6 months with Optune + TMZ (n=249) compared with 18.5 months with TMZ alone (n=123)1

Optune + TMZ improved median survival vs TMZ alone regardless of extent of resection

OS data from a post-hoc analysis in patients who had a partial resection or gross total resections in the EF-14 study (Optune® + TMZ vs TMZ alone)

*A randomized, open-label trial in 695 patients with newly diagnosed GBM whose tumor was resected or biopsied and had completed concomitant radiochemotherapy were randomized 2:1 to TTFields plus maintenance TMZ or TMZ alone.

GBM, glioblastoma; OS, overall survival; TMZ, temozolomide.

Results from the EF-14 study post-hoc analysis of biopsy-only patients

Learn about Optune + TMZ in biopsy-only patients

View this PDF

References: 1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 2. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).